| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 07/13/2000 | WO2000020445A3 Tumor antigens and ctl clones isolated by a novel procedure |
| 07/13/2000 | WO2000018801A3 Ncam binding compounds |
| 07/13/2000 | WO2000018351A3 Aglyco products and methods of use |
| 07/13/2000 | WO2000017366A3 Pharmaceutical composition for the pre-treatment of a patient in need of drug or pro-drug |
| 07/13/2000 | WO2000015800A3 Rac-like genes and methods of use |
| 07/13/2000 | WO2000015799A3 Rna-associated proteins |
| 07/13/2000 | WO2000015248A3 Growth factor-containing composition for healing tissue damage |
| 07/13/2000 | WO2000015208A3 New use of immunosupressants for mmp-mediated diseases |
| 07/13/2000 | WO2000015175A3 Use as an active substance of molecules binding to beta-1-integrin with the capacity to kill cells |
| 07/13/2000 | WO2000013683A3 Novel nitrophenylaziridine compounds and their use as prodrugs |
| 07/13/2000 | WO2000013501A9 Improved artificial blood fluids |
| 07/13/2000 | WO2000009734A9 Methods and compositions for use in spliceosome mediated rna trans-splicing |
| 07/13/2000 | WO2000009666A9 Differentiation of non-insulin producing cells into insulin producing cells by glp-1 or exendin-4 and uses thereof |
| 07/13/2000 | WO2000008196A9 Urate oxidase |
| 07/13/2000 | WO2000008153A9 Arf-p19, a novel regulator of the mammalian cell cycle |
| 07/13/2000 | WO2000007545A9 Apoptosis proteins |
| 07/13/2000 | WO2000006534A9 Compounds and compositions for delivering active agents |
| 07/13/2000 | WO1999065329A3 Dietary supplement containing colostrinin |
| 07/13/2000 | WO1999063097A9 Caspase-9 deficient animals and the use thereof |
| 07/13/2000 | WO1999060016A3 Antimicrobial cationic peptide derivatives of bactenecin |
| 07/13/2000 | WO1997020575A8 Targeted adenovirus vectors |
| 07/13/2000 | DE19917838A1 Composition for treating prion or other neurodegenerative diseases, comprises a peptide that inhibits unfolding of the prion to its pathological isoform |
| 07/13/2000 | DE19900743A1 Neue komplexbildende Proteine New complexing proteins |
| 07/13/2000 | DE19900709A1 Composition for prophylaxis or therapy, particularly as an adjuvant for antitumor vaccines, comprises an active agent bound to an adsorbent |
| 07/13/2000 | DE19900503A1 Verwendung einer Zusammensetzung zur Herstellung eines Arzneimittels zur Behandlung von Erkrankungen mit erhöhten extrazellulären FasL-Titern, Verfahren zur prophylaktischen Eignungs- bzw. Qualitätskontrolle derselben, Verfahren zur Herstellung von Arzneimitteln zur Behandlung obiger Krankheiten mit gesteigerter Wirksamkeit Use of a composition for the manufacture of a medicament for the treatment of diseases with increased extracellular FasL titers method for the prophylactic or suitability quality control thereof, a process for the preparation of medicaments for the treatment of the above diseases with enhanced efficacy |
| 07/13/2000 | DE19845405C2 Arylsubstituierte Propanolaminderivate und deren Verwendung Aryl-substituted Propanolaminderivate and their use |
| 07/13/2000 | CA2753331A1 Soluble receptor br43x2 and methods of using |
| 07/13/2000 | CA2702760A1 Insulin-like growth factor (igf) i mutant variants |
| 07/13/2000 | CA2363839A1 Wound healing and orofacial clefting |
| 07/13/2000 | CA2360396A1 Characterization of a calcium channel family |
| 07/13/2000 | CA2360381A1 Methods for treating cystic fibrosis |
| 07/13/2000 | CA2359892A1 Methods of eliciting broadly neutralizing antibodies targeting hiv-1 gp41 |
| 07/13/2000 | CA2359853A1 Human chemokine beta-10 mutant polypeptides |
| 07/13/2000 | CA2358955A1 N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase |
| 07/13/2000 | CA2358939A1 3-(thio-substituted amido)-lactams useful as inhibitors of matrix metalloproteinase |
| 07/13/2000 | CA2358851A1 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
| 07/13/2000 | CA2358754A1 Synergistic tumorcidal response induced by histamine |
| 07/13/2000 | CA2358609A1 Process for producing activated protein |
| 07/13/2000 | CA2358543A1 Human desaturase gene and uses thereof |
| 07/13/2000 | CA2358495A1 Prolonged release microsphere encapsulating luteinizing hormone-releasing hormone analogues and method for preparing the same |
| 07/13/2000 | CA2358491A1 Antitumor agents |
| 07/13/2000 | CA2358430A1 Potentiation of anti-cd38-immunotoxin cytotoxicity |
| 07/13/2000 | CA2358427A1 Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13 |
| 07/13/2000 | CA2358426A1 Methods and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors |
| 07/13/2000 | CA2358296A1 Targeted transscleral controlled release drug delivery to the retina and choroid |
| 07/13/2000 | CA2358212A1 Formulations for treating disease and methods of using same |
| 07/13/2000 | CA2358119A1 Compositions and methods relating to cyclic compounds that undergo nucleotide base pair-specific interactions with double-stranded nucleic acids |
| 07/13/2000 | CA2358014A1 Gene therapy to promote angiogenesis |
| 07/13/2000 | CA2357811A1 Nucleic acids and proteins corresponding to mutants of g-csf with granulopoietic activity |
| 07/13/2000 | CA2357807A1 Human seven-transmembrane receptors |
| 07/13/2000 | CA2357677A1 Insulin-synthesis genes |
| 07/13/2000 | CA2357146A1 Human cyclic nucleotide pdes |
| 07/13/2000 | CA2356937A1 Recombinant herpes simplex virus useful for treating neoplastic disease |
| 07/13/2000 | CA2356919A1 Selective inhibitors of mmp-12 |
| 07/13/2000 | CA2356412A1 Screening method |
| 07/13/2000 | CA2356401A1 Expression and export of anti-obesity proteins as fc fusion proteins |
| 07/13/2000 | CA2355859A1 Gene therapy-1 |
| 07/13/2000 | CA2354638A1 Expression of secreted human alpha-fetoprotein in transgenic animals |
| 07/13/2000 | CA2354531A1 Polyol compounds, their production and use |
| 07/13/2000 | CA2354194A1 Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells |
| 07/13/2000 | CA2353634A1 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents |
| 07/13/2000 | CA2350946A1 Method of treating sexual disturbances |
| 07/12/2000 | EP1018558A2 Hepatitis C Virus Epitopes |
| 07/12/2000 | EP1018552A1 Production of pluripotent granulocyte colony-stimulating factor |
| 07/12/2000 | EP1018551A1 Megsin protein |
| 07/12/2000 | EP1018550A2 Allergenic protein and peptides from house dust mite and uses thereof |
| 07/12/2000 | EP1018518A2 Use of autoantibodies for tumor therapy and prophylaxis |
| 07/12/2000 | EP1018517A2 Binding agents to CD23 for treatment of inflammatory, autoimmune or allergic diseases |
| 07/12/2000 | EP1018344A2 HLA-restricted hepatitis B virus CTL epitopes |
| 07/12/2000 | EP1018343A1 Use of p97 and iron binding proteins as diagnostic and therapeutic agents |
| 07/12/2000 | EP1018342A2 Diagnosis and treatment of bacterial dysentery |
| 07/12/2000 | EP1018341A1 Antistress agents and functional foods |
| 07/12/2000 | EP1018003A1 Modulators of dna cytosine-5 methyltransferase and methods for use thereof |
| 07/12/2000 | EP1017980A2 Methods of the identification of pharmaceutically active compounds |
| 07/12/2000 | EP1017846A1 Control of immune responses by modulating activity of glycosyltransferases |
| 07/12/2000 | EP1017835A1 Methods of using cytochrome p450 reductase for the enhancement of p450-based anti-cancer gene therapy |
| 07/12/2000 | EP1017829A2 Fusion proteins comprising a dimerization, trimerization or tetramerization domain and an additional heterologous transcription activation, transcription repression, dna binding or ligand binding domain |
| 07/12/2000 | EP1017828A1 HUMAN COMPLEMENT C3-DEGRADING PROTEINASE FROM $i(STREPTOCOCCUS PNEUMONIAE) |
| 07/12/2000 | EP1017827A1 New human cathepsin |
| 07/12/2000 | EP1017823A2 Engineered protein kinases which can utilize modified nucleotide triphosphate substrates |
| 07/12/2000 | EP1017818A2 Macrophage derived chemokine (mdc), mdc analogs, mdc inhibitor sustances, and uses thereof |
| 07/12/2000 | EP1017817A2 Mutants of thyroid stimulating hormone and methods based thereon |
| 07/12/2000 | EP1017812A1 Telomere repeat binding factors and diagnostic and therapeutic use thereof |
| 07/12/2000 | EP1017810A1 Agonist and antagonist peptides of carcinoembryonic antigen (cea) |
| 07/12/2000 | EP1017809A2 Human regulatory molecules |
| 07/12/2000 | EP1017808A2 53bp2 complexes |
| 07/12/2000 | EP1017807A1 Osf2/cbfa1 compositions and methods of use |
| 07/12/2000 | EP1017806A2 Compositions and methods for conferring tick immunity and preventing tick borne diseases |
| 07/12/2000 | EP1017804A2 A single gene encoding aortic-specific and striated-specific muscle cell isoforms and uses thereof |
| 07/12/2000 | EP1017801A2 Composition and method for enhancing paracellular transport across cell layers |
| 07/12/2000 | EP1017800A1 Antisense oligonucleotides against thymidylate synthase |
| 07/12/2000 | EP1017798A1 Lunasin peptides |
| 07/12/2000 | EP1017786A1 I-(kappa)- b(kinases) |
| 07/12/2000 | EP1017723A2 Costimulating t-cell polypeptide, monoclonal antibodies, their preparation and use |
| 07/12/2000 | EP1017722A2 Compounds with anti-ks and anti-hiv activity |
| 07/12/2000 | EP1017721A1 Recombinant mhc molecules useful for manipulation of antigen-specific t-cells |
| 07/12/2000 | EP1017720A1 Site-directed chemotherapy of metastases |
| 07/12/2000 | EP1017719A1 Secreted proteins and polynucleotides encoding them |
| 07/12/2000 | EP1017718A1 Novel gene defective in apeced and its use |
| 07/12/2000 | EP1017716A1 Car receptors and related molecules and methods |